Corporate Banner
Satellite Banner
Technology Networks Header
Thursday, February 23, 2012
Technology Networks
 
Register |
Home Page>Events
  Events
February 2012
Scientific News
Launch of DIRECT - An Innovative Medicines Initiative Project for Personalized Medicine in Diabetes
Academia and the pharmaceutical industry working together in the fight against diabetes.
NIH Common Fund Researchers Uncover Structure of Important Target for Drug Design
Researchers have uncovered a potent class of small molecules that selectively turn on the S1P1 receptor.
Drug Halts Organ Damage in Inflammatory Genetic Disorder
NIH study shows benefits of long-term Kineret therapy in people with NOMID.
Rapid Bone Loss Possible Side Effect of Anti-Obesity Drug
Research from UT Southwestern Medical Center has raised concern about the safe use of fibroblast growth factor 21.
Compugen Cancer Target Results Demonstrate Significant Potential for Cancer Immunotherapy
Findings support CGEN-15001T's potential as a powerful drug target for cancer immunotherapy.
Synthesis, Characterization and Biological Activity Studies of 1,3,4-Oxadiazole Analogs
Some of the compounds prepared were shown to possess remarkable antibacterial, antifungal and anti-inflammatory activities.
Natural Product Biosyntheses in Cyanobacteria: A Treasure Trove of Unique Enzymes
Researchers from the University of Potsdam review biochemical studies of cyanobacterial pathways and how this can inspire the development of concepts for the design of bioactive compounds.
Ganetespib Synergizes with Taxanes in Multiple Non-small Cell Lung Cancer Models
Combination of ganetespib with microtubule stabilizers, docetaxel and paclitaxel, or destabilizers, vincristine, was shown to result in synergistic anticancer activity.
Idera Pharmaceuticals Announces Selection of Toll-like Receptor (TLR) Agonist Candidates for Evaluation as Vaccine Adjuvants by Merck
The partners announced the selection of several novel agonists targeted to TLR7, TLR8 or TLR9 for evaluation and use as vaccine adjuvant candidates under the companies' collaboration and license agreement.
SCYNEXIS and Medicines for Malaria Venture (MMV) Sign HEOS® Agreement
The software is a comprehensive, web-based drug research information management system that supports geographically distributed scientists and facilitates collaboration.
Company Logo
08 Feb 2012 - 09 Feb 2012
Budapest, Hungary
PHARM Connect Congress 2012
Company Logo
15 Feb 2012 - 17 Feb 2012
London, UK
4th Annual Predictive Toxicology Summit
Company Logo
20 Feb 2012 - 22 Feb 2012
Lyon, France
The International Conferences on Microreaction Technology
Company Logo
20 Feb 2012 - 21 Feb 2012
London, UK
Advances and Progress in Drug Design
27 Feb 2012 - 28 Feb 2012
Red Rock Casino, Resort & Spa, Las Vegas, NV
2nd Ubiquitin Research and Drug Discovery Conference








Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Get The App
Go to LabTube.tv
Go to ePosters.net